Federal contract award
75N93020C00020
TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $22.0M |
| Current contract value | $22.0M |
| Potential contract value / ceiling | $27.0M |
| Start date | Jul 1, 2020 |
| Current end date | Jan 31, 2027 |
| Potential end date | Jan 31, 2027 |
| Latest award activity | Aug 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 17 of 17 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 20, 2026 | P00016 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Apr 23, 2026 | P00015 | $1.6M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Jan 7, 2026 | P00014 | $2.0M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Dec 23, 2025 | P00013 | $0 | DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR ANTIBIOTIC RESISTANT BACTERIA |
| Sep 4, 2025 | P00012 | $-1 | TO DEOBLIGATE FY 2020 5TH YEAR FUNDS ON LINE 1. TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| May 13, 2025 | P00011 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Nov 26, 2024 | P00010 | $1.6M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Jun 7, 2024 | P00009 | $970.6K | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Aug 31, 2023 | P00008 | $2.7M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Jan 23, 2023 | P00007 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Sep 29, 2022 | P00006 | $140.8K | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Sep 20, 2022 | P00005 | $5.8M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Dec 10, 2021 | P00004 | $3.7M | EO14042 - TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Sep 23, 2021 | P00003 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| May 18, 2021 | P00002 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Apr 26, 2021 | P00001 | $0 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
| Jun 29, 2020 | 0 | $3.7M | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. |
Estimated positioning window
Nov 1, 2026 – Jan 30, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-01-31 (91 days from calculation)
- +35 points
- 155 historical awards in this buyer and category group
- +15 points
- 17 recorded award transactions
- +10 points
- Latest award action: 2026-08-20
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.